Rachel Riechelmann
@RachelRiechelm2
Clin Oncology Director-AC Camargo Cancer Canter 🇧🇷focus: neuroendocrine tumors, colorectal/anal cancer. Love animals, travels, research. All are born equal.
ID:1147280863039819777
05-07-2019 23:07:27
1,3K Tweets
1,7K Followers
147 Following
Launching our Special Collection for #IWD2024 on Women’s Research In TAM. Introducing the fantastic Associate Editors who are Guest Editing the collection: Rachna Shroff, MD, FASCO Hanneke van Laarhoven KSridhar, Rachel Riechelmann
journals.sagepub.com/topic/collecti… #WomensDay #OncologyResearch
1/11
🗣️🌍👩🏻⚕️👨🏻⚕️ ASCO JCO Global Oncology published Competencies for Global Oncology Training
🔸Knowledge & Skills need in global health & cancer specific care
🔹 Understand disparities, define resources in LMICs & promote international collaboration
#globaloncology OncoAlert OncoDaily
So happy to share my first Nature Nature Reviews Disease Primers publication, together with brilliant colleagues Garcia-Carbonero's Lab
Giuseppe Lamberti, Panzuto, Pavel, O’Toole, Ambrosini, Falconi, Rindi & Campana. on Gastric
#neuroendocrinecancer
go.nature.com/4aHikWE
Our NEW Primer on Gastric neuroendocrine neoplasms is live today!
By Giuseppe Lamberti, Panzuto, Pavel, O’Toole, Ambrosini, Falconi, Garcia-Carbonero, Rachel Riechelmann, Rindi & Campana.
Check it out here:
go.nature.com/4aHikWE
Great honor and responsibility! Thank you Eric J. Small ASCO President elect and Robin Zon ASCO President for inviting me to be in Annual Meeting Education Program Committee and to become the Chair Elect for the Annual Meeting Education Program Committee 2025-26 @asco Instituto Nacional de Cancerología
Neoadjuvant chemo (NAC) has benefit in OPTICAL and FOxTROT!
👏🏽to all authors!
A 🧵
ascopubs.org/doi/10.1200/JC…
Jenny Seligmann
Come to see David Kaldas,MD,MS from USF News presenting our poster about MUTYH-CRC cases seen at Moffitt Cancer Center revealing an extremely high incidence of targetable alterations: KRAS G12C (24%), MSI-H (17%), BRAF (14%) and BRCA2 (11%)
aacrjournals.org/cancerres/arti…
#TumorBoardTuesday Mike Pishvaian Integrity CE, LLC Dr. Shubham Pant PanCAN Lustgarten Foundation 7/17 #TumorBoardTuesday
Mini Tweetorial 3👨🏽🏫
@Kevansf & team found a way to build a molecule that irreversibly binds cysteine (G12C), outside of the GTP binding pocket!
This causes 🔗rxn which changes shape of GTP binding pocket. Bottom line: GTP can't bind & KRAS is locked ❌
#TumorBoardTuesday Mike Pishvaian Integrity CE, LLC Dr. Shubham Pant PanCAN Lustgarten Foundation Kevan Shokat NEJM UCSF Helen Diller Family Comprehensive Cancer Ctr KRASKickers 15/17 #TumorBoardTuesday
If we can ❌KRAS, will ❌EGFR at the same time work better?
Active area of research--combos are promising so far!
Adagrasib + cetuximab= DOUBLED ORR in #CRC and now supported in #NCCN
Ongoing work in PDAC
Encouraging results of the bispecific DLL3/CD3 engager BI 764532 in extrapulmonary NEC. As expected, outstanding presentation by Jaume Capdevila
In case you missed out…
In this Journal Club, Dr. Rodrigo Taboada & Rachel Riechelmann from A.C.Camargo Cancer Center discuss the importance of a study outlining a novel neuroendocrine neoplasm classification system
Sakti Chakrabarti, MD ASCO Dr Amit Mahipal Alok Khorana, MD Smitha Krishnamurthi Kristen Ciombor Aparna Raj Parikh Tanios Bekaii-Saab, MD Ibrahim Halil SAHIN, MD Rachna Shroff, MD, FASCO Scott Kopetz I fully support 👏🏻👍 ESMO - Eur. Oncology GI #cancer journal. It’s NEW and supports ALL GI research. It’s not just our EU/UK colleagues. The editorial board is INT’L including myself, Yelena Y. Janjigian MD Rachel Riechelmann Karyn Goodman, MD, MS Erika Ruiz-Garcia. We encourage you to submit! #CancerResearch
Scientific Co-Chairs, Eric Van Cutsem, Ducreux Michel & Teresa Macarulla, as well as members of the Scientific Committee & experts in the field, give their reasons why you should attend #ESMOGI24 , on 26-29 June, in Munich. Register by 10 April and save.
🔗ow.ly/K5hS50QBGO5
